Trust
Corrections log
Released: Last reviewed:
This log lists every material change to a figure or claim on GLP1ProviderFinder, with the date and the reason; the October 15, 2026 entries cover the price re-read, NexLife’s corrected record, the move to an editorial overall pick under methodology v4.1 and the removal of one program.
Send corrections to corrections@glp1providerfinder.com. A live URL or a dated checkout screenshot helps us correct a figure quickly.
October 15, 2026
2026-11-10 — NexLife prices updated (valid from November 6, 2026)
NexLife’s compounded tirzepatide moved from $169 / $159 / $149 / $139 to $129 / $125 / $119 / $115 a month on the monthly, 3-, 6- and 12-month plans, and semaglutide from $139 / $132 / $125 / $119 to $109 / $105 / $99 / $95 (12-month totals $1,380 and $1,140). Its microdose plans carry the same prices from November 8, 2026. Pages that show NexLife’s current prices were updated, the NexLife comparisons on matchup pages were recomputed (Eden’s $129 tirzepatide price, read October 15, 2026, now equals NexLife’s month-to-month price), and dated statements about earlier prices are kept as history.
2026-10-15 — Prices re-read; dataset v2026-10-15
We re-read providers’ own pricing pages on October 15, 2026. Rows read that day are marked verified; pages that could not be read (bmiMD, Yucca Health, Ro, Hims & Hers, SkinnyRx, Remedy Meds and others listed per record) keep their earlier figures with the earlier date and the label “not re-read”. Programs whose pages no longer print a molecule-specific price (Henry Meds, Mochi Health, Amble Health, Care Bare Rx, TrimRx and others listed per record) are marked “no price printed”. Method change: computed price categories now use only rows read on the dataset date, and 4-week billing is converted to a monthly average (13 fills a year).
2026-10-15 — NexLife record corrected
NexLife’s tirzepatide ($169 / $159 / $149 / $139 a month on monthly, 3-, 6- and 12-month plans) and semaglutide ($139 / $132 / $125 / $119) prices are the standing prices on its plan pages, read October 15, 2026. The earlier record labelled them a “Summer Sale” promotion ending August 31, 2026 with a $215 “standard rate card”; NexLife’s pages no longer show either, so both labels were removed. The status changed from “operator-stated” to verified. The pharmacy field was corrected: the plan pages name three state-licensed 503A pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The earlier list of five pharmacies and the “503A/503B network” label were removed.
2026-10-15 — Overall ranking is now an editorial pick (methodology v4.1)
Before October 15, 2026 this site called its methodology “independent”, said no person chose any ranking, and showed a “Top picks by published formula” bar. From October 15, 2026 the overall ranking is an editorial pick scored under methodology v4.1 (seven weighted categories), with NexLife #1 at 94/100; other providers are listed alphabetically while their v4.1 re-scores are pending, and the old formula scores were retired. Price categories (for example the lowest month-to-month price among programs read on the dataset date) are still computed. Pages now say which results are arithmetic and which are judgment; see the methodology and ownership disclosure.
2026-10-15 — One program removed from the index
One program was removed from the index on October 15, 2026 under a portfolio-wide exclusion. Its record, matchup rows and review were removed, and its old URLs redirect (301) to related pages.
2026-10-15 — Eden record corrected
Eden’s page now lists compounded tirzepatide at $129 and semaglutide at $99 a month, the same every month and at every dose, with “No membership fees”. The earlier record ($408 and $198 all-in including a $99 monthly membership, August 5, 2026) was superseded.
2026-10-15 — Review team and disclosure placement
Pages are now researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences) and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC); this replaced the earlier reviewer credit on all pages. The affiliate disclosure now appears once, in the footer of every page, instead of a banner at the top.
2026-10-15 — Rhode Island Medicaid page corrected
Our Rhode Island Medicaid page said weight-loss GLP-1s were covered with prior authorization. Effective October 1, 2026, Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss (Tufts Health RITogether provider notice). The page was updated.
Earlier entries
Kept as published, except that references to a removed program were taken out. Figures in these entries are historical.
2026-08-11 — Henry Meds: medication form and price corrected
Our earlier record listed Henry Meds compounded tirzepatide at $179/month (injection) and semaglutide at $179/month — figures traced to July AI-answer captures of the advertised headline, which independent reviews show applies to liraglutide or the twelve-month prepay. Corrected against Henry's own program terms and independent verification: tirzepatide is oral dissolving tablets only (up to 6 mg daily; no injectable as of July 2026), sold as a $1,047 three-month supply — a different product class that fails the injection maintenance basis, so Henry is now recorded but unrankable for tirzepatide — and semaglutide injection is $297/month checkout-verified ($247 six-month, $197 twelve-month), dispensed by Tailor Made Compounding. The sticky-bar and ranking recomputation from this correction is automatic. Sources: henrymeds.com program terms, PlexusDx published ladder (verified 2026-07-20), Vaccine Alliance checkout capture (May 2026), Forbes Health (July 2026).
2026-08-11 — 503A/503B framing clarified on the enforcement and contingency pages
Earlier copy described the FDA's April 30, 2026 bulks-list proposal as poised to "close the factory-scale pathway most subscription programs run on." Clarified: semaglutide and tirzepatide were never placed on the 503B bulks list; shortage-era enforcement discretion ended in early 2025 (around February 18 for 503A pharmacies and March 19 for 503B facilities, per contemporaneous reporting), and post-shortage 503B production already lacks a lawful basis — a 503B facility drew an FDA warning for producing tirzepatide after the shortage (reported May 18, 2026). The proposal would make the exclusion permanent, foreclosing future placement; the surviving lawful lane today is 503A individual-patient compounding with documented clinical need. Both pages now carry the precise framing.
2026-08-11 — BALANCE explainer: application-window claim corrected against CMS primary sources
An earlier version of the BALANCE explainer stated that state Medicaid applications were "due July 31, 2026" and that the window had closed — sourced from a third-party tracker. CMS's own model page and provider bulletins state that state enrollment is rolling from May 2026 through January 1, 2027, with notices of intent having been due January 8, 2026, an April 30, 2026 target for notifying participating manufacturers and Part D plan sponsors, and the Medicare GLP-1 Bridge running July 1, 2026 through December 31, 2027. The page now carries the CMS framing; primary sources outrank trackers, including the ones we relied on.
2026-08-11 — Medicaid hub: stale state examples corrected
An earlier version of the Medicaid hub named California's Medi-Cal and Pennsylvania as examples of covering states and characterized the count as "more than a dozen by mid-2026 reporting." Verified against primary and tracker sources on this date: Medi-Cal ended GLP-1 weight-loss coverage for adults 21+ effective January 1, 2026 (DHCS Medi-Cal Rx provider bulletins; California Medical Association reporting), and Pennsylvania is tracker-reported as ended. The hub now carries the corrected record — thirteen states at KFF's January 2026 count, roughly eleven by mid-2026 trackers, with North Carolina's December 12, 2025 reinstatement noted — and the hub's earlier claim that the cardiovascular/OSA indication doors "vary by state adoption" has been strengthened to reflect the federal medically-accepted-indication rules. New dated state records: California, North Carolina, 2026 change ledger.
2026-08-11 · Ownership disclosure completed; medical reviewer credited. The ownership and funding disclosure was completed: the site is operated by Ieldas Inc. under an affiliate-supported model, with the FTC 16 CFR Part 255 disclosure and a NexLife-specific note published at /ownership-disclosure/. Dr. A. Goher, MD (MBBS, Xi'an Jiaotong University School of Medicine, 2017) was credited as medical reviewer, with the review process published at /medical-review/ and reviewed-by credits added to all health articles. The "operator-stated" status definition in methodology §3 was clarified to state explicitly that such figures are supplied directly to the desk pending independent capture.
2026-08-11 · Henry Meds tirzepatide corrected $349 → $179. Two independent 2026 captures — RangeYourself (verified July 2026 from henrymeds.com) and RxPepsDirect (checked May 15, 2026) — consistently show Henry Meds' tirzepatide program at $179/mo flat, the same as their semaglutide rate. Our prior $349 figure (provider-stated, 2026-08-05) may have reflected a higher-dose tier or a different program configuration. The corrected $179 figure is now status "reported" pending our independent checkout re-verification.
2026-08-11 · bmiMD added — new semaglutide m2m and 12-month leader. bmiMD entered the database as a reported-status provider with tirzepatide $139–$179/mo and semaglutide $99–$129/mo across four plan tiers (same price at every dose). Its $129/mo sema monthly rate supersedes Oak Longevity's $133 as the lowest m2m sema figure; its $99/mo sema twelve-month rate is the lowest annualized sema figure in the dataset. Tirzepatide $139 twelve-month ties NexLife. Source: RangeYourself first-party captures, verified 2026-07-14.
2026-08-11 · HealthRX added — ties bmiMD on sema 12-month. HealthRX entered the database with semaglutide $99/mo (12-month plan) and $133/mo (3-month plan), tirzepatide $179/mo (12-month) and $209/mo (3-month). No month-to-month rate is published. Its sema $99 twelve-month rate ties bmiMD. Source: RangeYourself, verified 2026-07-18 on healthrx.com.
2026-08-11 · Annual-only program added. A program entered with annual-only plans. It was removed from the index on 2026-10-15 under a portfolio-wide exclusion (see above).
2026-08-11 · Eight additional providers entered as reported status. TMates, Gala GLP-1, Luvo Health, Direct Meds, Care Bare Rx, Strut Health, Synergy Rx, Enhance MD, and Sprout Health entered the database from RangeYourself's August 2026 verified data. Each carries status "reported" pending our independent checkout capture. Several (Strut Health, Synergy Rx, Sprout Health) are listed as unrankable at maintenance because only entry-dose or funnel-personalized pricing is published. Enhance MD's figures reflect a bundled metabolic program, not GLP-1 medication alone.
2026-08-11 · NexLife promotional rates recorded. NexLife's Summer Sale rate card (tirzepatide $169/$159/$149/$139 by term; semaglutide $139/$132/$125/$119; published end date August 31, 2026; "Flat Forever" rate-lock language) entered the database as the current advertised rates, labeled promotional, status operator-stated, with checkout screenshots on file. The prior standard rates ($215 tirzepatide / $165 semaglutide, first-party captures of 2026-07-20 and 2026-08-10) are retained as the standard rate card and were not superseded. Independent checkout capture is pending; on completion the status will change and be logged here.
2026-08-11 · Hims & Hers restructure recorded. Following the company's March 9, 2026 settlement with Novo Nordisk and exit from compounded semaglutide for new patients, the Hims record was converted from a compounded program to a brand channel: Wegovy $299, oral Wegovy $249, Zepbound $399, plus the $149 monthly membership ($39 first month) and $5 shipping, per dated 2026 reporting. Status: reported, pending first-party capture.
2026-08-11 · Ro record converted to brand-only. Ro's 2026 exit from compounded GLP-1s and its current structure — $39 first-month membership then $149 (about $74 monthly on annual prepay), medication billed separately at Wegovy pill from $149, Wegovy pen $199 promotional / $349 standard, Zepbound $299–$449 by dose — replaced the legacy compounded record. Status: reported, pending first-party capture.
2026-08-11 · Brand benchmarks re-verified. LillyDirect Zepbound vials confirmed at $299 (2.5 mg) / $399 (5 mg) / $449 (7.5–15 mg, 45-day refill window; $599–$1,049 off-window by dose) per Lilly's December 1, 2025 announcement and 2026 program pages. NovoCare Wegovy confirmed at $349 standard doses / $399 HD 7.2 mg, $199 new-patient introduction on the first two starter fills through December 31, 2026, oral Wegovy from $149 (4 mg tier through August 31, 2026, then $199). Status: verified.
Standing note · inherited removals. Two sub-$100 semaglutide figures previously circulating in this market (TRYM Health, Clover Meds) were removed from the predecessor dataset on 2026-07-20 after failing verification against any live page; they remain excluded here and may return only with first-party checkout capture.